EP2646580A4 - Methods for detecting neurodegenerative diseases or disorders - Google Patents

Methods for detecting neurodegenerative diseases or disorders

Info

Publication number
EP2646580A4
EP2646580A4 EP11845574.0A EP11845574A EP2646580A4 EP 2646580 A4 EP2646580 A4 EP 2646580A4 EP 11845574 A EP11845574 A EP 11845574A EP 2646580 A4 EP2646580 A4 EP 2646580A4
Authority
EP
European Patent Office
Prior art keywords
disorders
methods
neurodegenerative diseases
detecting neurodegenerative
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11845574.0A
Other languages
German (de)
French (fr)
Other versions
EP2646580A1 (en
Inventor
Mark Chen
Ryan J Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP2646580A1 publication Critical patent/EP2646580A1/en
Publication of EP2646580A4 publication Critical patent/EP2646580A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/501—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the head, e.g. neuroimaging or craniography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11845574.0A 2010-11-29 2011-11-28 Methods for detecting neurodegenerative diseases or disorders Withdrawn EP2646580A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41770110P 2010-11-29 2010-11-29
PCT/US2011/062250 WO2012074933A1 (en) 2010-11-29 2011-11-28 Methods for detecting neurodegenerative diseases or disorders

Publications (2)

Publication Number Publication Date
EP2646580A1 EP2646580A1 (en) 2013-10-09
EP2646580A4 true EP2646580A4 (en) 2014-05-14

Family

ID=46172233

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11845574.0A Withdrawn EP2646580A4 (en) 2010-11-29 2011-11-28 Methods for detecting neurodegenerative diseases or disorders

Country Status (10)

Country Link
US (1) US20140255301A1 (en)
EP (1) EP2646580A4 (en)
JP (1) JP2014507115A (en)
KR (1) KR20130142144A (en)
CN (1) CN103228799A (en)
BR (1) BR112013012943A2 (en)
CA (1) CA2818010A1 (en)
MX (1) MX2013005796A (en)
RU (1) RU2013129860A (en)
WO (1) WO2012074933A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105403649B (en) * 2015-12-01 2018-03-20 深圳大学 A kind of detection AD urine polypeptide group AD biomarkers
WO2018075685A1 (en) * 2016-10-18 2018-04-26 The Regents Of The University Of California Method for positron emission tomography (pet) imaging analysis for classifying and diagnosing of neurological diseases
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
CN109696549B (en) * 2017-10-20 2022-11-01 成都蓝瑙生物技术有限公司 Luminous ELISA in-vitro diagnostic kit for cerebral apoplexy
WO2019129029A1 (en) * 2017-12-29 2019-07-04 北京泱深生物信息技术有限公司 Gene as marker for diagnosing and treating parkinson's disease and use thereof
WO2019136300A2 (en) * 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof
CN108377266A (en) * 2018-02-07 2018-08-07 安徽星网软件技术有限公司 A kind of Real-time Data Transfer Method and system based on car networking
US20230210441A1 (en) 2020-06-01 2023-07-06 Nec Corporation Brain image analysis apparatus, control method, and computer readable medium
CN116626294A (en) * 2022-09-20 2023-08-22 菲创生物医学技术(广州)有限公司 Use of discoid domain receptor 2 in diagnosis of neurodegenerative diseases and related computer readable media

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005076939A2 (en) * 2004-02-09 2005-08-25 University Of Kentucky Research Foundation Assay and method for diagnosing and treating alzheimer’s disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHAPMAN D L ET AL: "Tbx6, a mouse T-Box gene implicated in paraxial mesoderm formation at gastrulation.", DEVELOPMENTAL BIOLOGY 15 DEC 1996, vol. 180, no. 2, 15 December 1996 (1996-12-15), pages 534 - 542, XP002722497, ISSN: 0012-1606 *
CHAPMAN D L ET AL: "Three neural tubes in mouse embryos with mutations in the T-box gene Tbx6.", NATURE 12 FEB 1998, vol. 391, no. 6668, 12 February 1998 (1998-02-12), pages 695 - 697, XP002722496, ISSN: 0028-0836 *
DJUROVIC SRDJAN ET AL: "A genome-wide association study of bipolar disorder in Norwegian individuals, followed by replication in Icelandic sample.", JOURNAL OF AFFECTIVE DISORDERS OCT 2010, vol. 126, no. 1-2, October 2010 (2010-10-01), pages 312 - 316, XP002722495, ISSN: 1573-2517 *
GAVRILOV SVETLANA ET AL: "Tbx6 is a determinant of cardiac and neural cell fate decisions in multipotent P19CL6 cells.", DIFFERENTIATION; RESEARCH IN BIOLOGICAL DIVERSITY SEP 2012, vol. 84, no. 2, September 2012 (2012-09-01), pages 176 - 184, XP002722494, ISSN: 1432-0436 *
KLEIN ULF ET AL: "The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.", CANCER CELL 19 JAN 2010, vol. 17, no. 1, 19 January 2010 (2010-01-19), pages 28 - 40, XP002722498, ISSN: 1878-3686 *
See also references of WO2012074933A1 *

Also Published As

Publication number Publication date
BR112013012943A2 (en) 2020-08-11
JP2014507115A (en) 2014-03-27
US20140255301A1 (en) 2014-09-11
CN103228799A (en) 2013-07-31
KR20130142144A (en) 2013-12-27
RU2013129860A (en) 2015-01-10
MX2013005796A (en) 2013-07-29
EP2646580A1 (en) 2013-10-09
CA2818010A1 (en) 2012-06-07
WO2012074933A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
HRP20181423T1 (en) Gene therapy for neurodegenerative disorders
HK1209793A1 (en) Methods of detecting diseases or conditions
HK1183021A1 (en) Imaging agents for detecting neurological disorders
GB2501210B (en) Road guidance system for visually impaired
EP2611765A4 (en) Methods for treating neurodegenerative diseases
EP2854942A4 (en) Systems and methods for detecting health disorders
EP2646580A4 (en) Methods for detecting neurodegenerative diseases or disorders
EP2749456A4 (en) Parking assist apparatus
ZA201200707B (en) Parking lot
ZA201307591B (en) Micro-devices for disease detection
EP2724896A4 (en) Parking assistance device
EP2662260A4 (en) Travel situation detection system
EP2692966A4 (en) Parking facility
EP2776295A4 (en) Parking assisting system
EP2596133A4 (en) Methods of detecting neurological or neuropsychiatric diseases or conditions
EP2596117A4 (en) Methods of detecting kidney-associated diseases or conditions
IL221415A0 (en) Compounds useful for treating neurodegenerative disorders
EP2653872A4 (en) Biomarker for amyloid-beta -related neurological disorders
NZ611793A (en) Apparatus for disease detection
GB201306866D0 (en) Neurodegenerative Disorders
GB201403183D0 (en) Detection of neurodegenerative disease
GB201117142D0 (en) Detection system
GB0902660D0 (en) Biomarkers for neurodegenerative diseases
GB201121430D0 (en) Trunklid sensing system
GB201111764D0 (en) Sensor system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130701

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140416

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20140424BHEP

Ipc: C12Q 1/68 20060101ALI20140424BHEP

Ipc: G01N 33/53 20060101ALI20140424BHEP

Ipc: G01N 33/58 20060101ALI20140424BHEP

17Q First examination report despatched

Effective date: 20160701

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161112